冷循环射频消融治疗大血管旁肝恶性肿瘤的安全性和有效性分析  

Efficacy and safety of percutaneous radiofrequency ablation for perivascular malignant liver tumors

作　　者：陈丽羽[1] 汪丽菁[1] 王立平[1] 时开元[1] 刘俊平[1] 金鑫焱[1] 钱超文[1] 

机构地区：[1]浙江省肿瘤医院超声科,杭州310022

出　　处：《浙江医学》2013年第10期885-888,共4页Zhejiang Medical Journal

摘　　要：目的探讨经皮冷循环射频消融治疗大血管旁肝脏恶性肿瘤的安全性和有效性。方法经皮冷循环消融治疗肝脏恶性肿瘤患者297例共358枚结节,其中存在大血管旁结节的患者77例(79枚,血管旁组),分别将患者的临床资料、并发症发生情况、治疗后无瘤生存率及结节的局部残留复发情况与非血管旁的患者220例(279枚,非血管旁组)进行比较。结果两组患者均未发生射频相关死亡,血管旁组和非血管旁组患者的严重并发症发生率分别为3.9%与2.7%(P>0.05)。1、2、3年无瘤生存率血管旁组分别为54.3%、48.8%、35.5%,非血管旁组为59.7%、35.4%、30.7%(P>0.05)。血管旁组和非血管旁组结节的局部复发率分别为22.8%、16.1%(P>0.05)。结论对于血管旁的肝恶性肿瘤,射频消融是一个安全而有效的治疗措施。Objective To evaluate the safety and efficacy of percutaneous radiofrequency ablation （RFA） for perivascular malignant liver tumors. Methods Total 297 patients with hepatic malignant tumors （358 nodules） underwent RFA using an inter-nal y cooled electrode, among them 77 patients had 79 nodules, which were〈5mm from the intrahepatic vessels and〉3mm in diameter （perivascular group）, and 220 patients had 279 nonperivascular nodules which were 〉5mm from large vessels（non-perivascular group）. The clinical data and outcomes were compared between two groups. Results There were no treat-ment-related death and the complication rate was similar in two group （3.9%vs 2.7%, P〉0.05）. The disease-free 1-, 2-, and 3-year survival rates in perivascular group were 54.3%, 48.8%and 35.5%, respectively, and those in nonperivascular group were 59.7%, 35.4%and 30.7%, respectively（P〉0.05）. There were no significant differences between perivascular and nonperivascular groups in local recurrence rate （22.8%vs 16.1%, P〉0.05）. Conclusion RFA is a safe and effective for treatment of perivascular malignant liver tumors.

关 键 词：肝肿瘤 门静脉 射频消融术 

分 类 号：R735.7[医药卫生—肿瘤]